Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study

Overview of attention for article published in Frontiers in immunology, May 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 50,220 followers.

Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study https://t.co/RnQ49EcPtA #LongCovid #pwLC

12 Jun 2024

Reply Repost Favourite

RT @BrendaCrabtreeR: Participants with advanced HIV and comorbid disease, reduced rates of AIDS-defining events and AEs with the immunologi…

28 May 2024

Reply Repost Favourite

Participants with advanced HIV and comorbid disease, reduced rates of AIDS-defining events and AEs with the immunologic recovery on fostemsavir-based treatment. Thank you for the leadership @DrBike7 https://t.co/o4UgTxc0ZW

28 May 2024

Reply Repost Favourite

Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study https://t.co/lAS795PREQ #FrontImmunol

28 May 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.